Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Muscular weakness and/or muscle wasting is recognized as a key medical problem in critically ill patients on intensive care units (ICUs) worldwide.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods and Results</h3><p>Intensive care unit‐acquired weakness (ICUAW) results from various diseases leading to critical illness and is observed in about 40% [1080/2686 patients, 95% confidence interval (CI): 38–42%] of mixed (medical–surgical) ICU patients. Muscle strength at ICU discharge is directly associated with mortality 5 years after discharge [hazard ratio 0.946, 95% CI: 0.928–0.968 per point increase in Medical Research Council (MRC) scores, <i>P</i> = 0.001]. ICUAW serves as umbrella term for the subgroups 'critical illness myopathy', 'critical illness polyneuropathy', and 'critical illness polyneuromyopathy', the latter distinguished using electrophysiology and/or biopsy studies. Diagnosing, studying, and developing treatments for ICUAW among the critically ill seems challenging due to the acuity and severity of the underlying heterogeneous diseases. Ventilator‐induced diaphragmatic dysfunction occurs in up to 80% (<i>n</i> = 32/40) of ICUAW patients after mechanical ventilation and mostly results from distinct muscular pathologies, disuse, underlying critical illness, and/or effects imposed directly by mechanical ventilation. Swallowing disorders/dysphagia likely represent an additional (local) neuromuscular dysfunction/ICUAW sequelae and presents in 10.3% (<i>n</i> = 96/933) of mixed medical–surgical ICU survivors, with 60.4% (<i>n</i> = 58/96) of patients remaining dysphagia positive until hospital discharge. Key independent risk factors for dysphagia following mechanical ventilation are baseline neurological disease [odds ratio (OR) 4.45, 95% CI: 2.74–7.24, <i>P</i> < 0.01], emergency admission (OR 2.04, 95% CI: 1.15–3.59, <i>P</i> < 0.01), days on mechanical ventilation (OR 1.19, 95% CI: 1.06–1.34, <i>P</i> < 0.01), days on renal replacement therapy (OR 1.1, 95% CI: 1–1.23, <i>P</i> = 0.03), and disease severity (Acute Physiology and Chronic Health Evaluation II score within first 24 h; OR 1.03, 95% CI: 0.99–1.07, <i>P</i> < 0.01). Dysphagia positivity independently predicts 28‐day and 90‐day mortality (90‐day univariate hazard ratio: 3.74; 95% CI, 2.01–6.95; <i>P</i> < 0.001) and is associated with a 9.2% excess (all‐cause) mortality rate. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Neuromuscular weakness and muscle wasting is observed in many survivors of critical illness. ICUAW, ventilator‐induced diaphragmatic dysfunction, and dysphagia are associated with complicated and prolonged ICU stay, impaired weaning from mechanical ventilation, impeded rehabilitative measures, and a considerable impact on morbidity and mortality is noted. Future research strategies should further explore underlying pathomechanisms and lead to development of causal treatment strategies.</p></section>

Incidence, one-year progression and factors associated with respiratory muscle weakness after discharge from ICU for COVID-19

Muscle weakness, functional capacities and recovery for COVID-19 ICU survivors

Potential Diaphragm Muscle Weakness-related Dyspnea Persists 2 Years after COVID-19 and Could Be Improved by Inspiratory Muscle Training: Results of an Observational and an Interventional Clinical Trial

Health-Related Quality of Life Improves in Parallel with FEV1 and 6-Minute Walking Distance Test at Between 3 and 12 Months in Critical COVID-19 Survivors

Intensive care unit-acquired weakness: A review from molecular mechanisms to its impact in COVID-2019

The association between inspiratory muscle strength and walking performance among people with post covid-19 condition; an observational study.

Persistent Fatigue, Weakness, and Aberrant Muscle Mitochondria in Survivors of Critical COVID-19

Functional ability and quality of life in critical illness survivors with intensive care unit acquired weakness: A secondary analysis of a randomised controlled trial

IMPACT OF PHYSICAL ACTIVITY LEVEL ON RESPIRATORY MUSCLE STRENGTH IN PATIENTS WITH POST-COVID-19 SYNDROME

Cardiorespiratory abnormalities in ICU survivors of COVID-19 with postacute sequelae of SARS-CoV-2 infection are unrelated to invasive mechanical ventilation

Health-related quality of life profiles, trajectories, persistent symptoms and pulmonary function one year after ICU discharge in invasively ventilated COVID-19 patients, a prospective follow-up study

A new phenotype of patients with post-COVID-19 condition is characterised by a pattern of complex ventilatory dysfunction, neuromuscular disturbance and fatigue symptoms

The effects of inspiratory muscle training on biomarkers of muscle damage in recovered COVID-19 patients after weaning from mechanical ventilation

A prospective clinical study on the mechanisms underlying critical illness myopathy-A time-course approach

Respiratory muscle strength in ischemic cardiomyopathy and COVID-19 patients.

Muscle Dysfunction and Functional Status in COVID-19 Patients during Illness and after Hospital Discharge

Muscular weakness and muscle wasting in the critically ill

Persistent disabilities 28 months after COVID-19 hospitalisation, a prospective cohort study

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

Diaphragm dysfunction after severe COVID-19: An ultrasound study

Decreased phrenic nerve compound muscle action potential, inspiratory muscle strength, and exercise capacity after COVID-19